share_log

藥明生物：截至二零二三年十二月三十一日止之全年業績公告

WUXI BIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 26 20:00
Summary by Futu AI
藥明生物公布截至2023年12月31日止全年業績，收益達人民幣17,034.3百萬元，同比增長11.6%。毛利微增1.5%至人民幣6,827.9百萬元，但純利下降21.5%至人民幣3,570.6百萬元。公司擁有人應佔純利亦下降23.1%至人民幣3,399.7百萬元。每股盈利由上年的1.06元下降至0.82元。董事會不建議派發任何末期股息。2023年，公司面臨多項挑戰，但依靠CRDMO平台及「跟隨並贏得分子」策略，實現穩健增長。下半年業務顯著反彈，綜合項目數增至698個。商業化生產項目數亦由去年的17個增至24個。未來，公司將繼續推進CRDMO業務模式，把握市場新機遇。
藥明生物公布截至2023年12月31日止全年業績，收益達人民幣17,034.3百萬元，同比增長11.6%。毛利微增1.5%至人民幣6,827.9百萬元，但純利下降21.5%至人民幣3,570.6百萬元。公司擁有人應佔純利亦下降23.1%至人民幣3,399.7百萬元。每股盈利由上年的1.06元下降至0.82元。董事會不建議派發任何末期股息。2023年，公司面臨多項挑戰，但依靠CRDMO平台及「跟隨並贏得分子」策略，實現穩健增長。下半年業務顯著反彈，綜合項目數增至698個。商業化生產項目數亦由去年的17個增至24個。未來，公司將繼續推進CRDMO業務模式，把握市場新機遇。
Pharmaceutical Biologics announced its full-year results for the year ended December 31, 2023, with revenues of RMB17,034.3 million, up 11.6% year-on-year. Gross profit marginally increased 1.5% to RMB6,827.9 million, but net profit fell 21.5% to RMB3,570.6 million. Company owners' net profit also fell 23.1% to RMB3,399.7 million. Earnings per share fell to $0.82 from $1.06 a year earlier. The Board of Directors does not recommend the distribution of any final dividend. In 2023, the company faces many challenges, but relies on the CRDMO platform and its “follow and win the molecule” strategy for solid growth. In the second half of the year, the total number of projects increased significantly to 698. The number of commercialized production projects also increased from 17 in the previous year to 24. In the future, the company will continue to advance the CRDMO business model and seize new opportunities in the market.
Pharmaceutical Biologics announced its full-year results for the year ended December 31, 2023, with revenues of RMB17,034.3 million, up 11.6% year-on-year. Gross profit marginally increased 1.5% to RMB6,827.9 million, but net profit fell 21.5% to RMB3,570.6 million. Company owners' net profit also fell 23.1% to RMB3,399.7 million. Earnings per share fell to $0.82 from $1.06 a year earlier. The Board of Directors does not recommend the distribution of any final dividend. In 2023, the company faces many challenges, but relies on the CRDMO platform and its “follow and win the molecule” strategy for solid growth. In the second half of the year, the total number of projects increased significantly to 698. The number of commercialized production projects also increased from 17 in the previous year to 24. In the future, the company will continue to advance the CRDMO business model and seize new opportunities in the market.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.